Pub. Date : 2013
PMID : 23555843
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets. | Valproic Acid | glycogen synthase kinase 3 beta | Homo sapiens |
| 2 | Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets. | Valproic Acid | glycogen synthase kinase 3 beta | Homo sapiens |
| 3 | Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets. | Valproic Acid | glycogen synthase kinase 3 beta | Homo sapiens |
| 4 | Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets. | Valproic Acid | glycogen synthase kinase 3 beta | Homo sapiens |
| 5 | Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets. | Valproic Acid | glycogen synthase kinase 3 beta | Homo sapiens |
| 6 | Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets. | Valproic Acid | glycogen synthase kinase 3 beta | Homo sapiens |